The Virus Clears Before the Patient Arrives

Dengue infects an estimated 390 million people per year and has no specific antiviral treatment, but the reason drug development has stalled is not that candidate molecules lack activity — it is that clinical trials cannot measure viremia in patients by the time they enroll. Dengue's peak viremic phase lasts 2–3 days and patients typically present to clinical care on day 3–5 of illness when viremia is already declining or undetectable. Designing a trial around viremia as the primary endpoint — the most direct measure of antiviral effect — means measuring an outcome that is largely over in the majority of enrolled patients. This is a trial design failure, not a drug failure, but it has produced the same result: two discontinued programmes and no approved treatment.

AT-752 (Atea Pharmaceuticals) was terminated after enrolling only 21 of 60 planned patients because 43% of placebo-arm participants already had viremia below the detection threshold at baseline enrollment — meaning the trial could not have detected a viremia-reducing effect even if the drug were fully active. JNJ-1802 (Johnson & Johnson) was discontinued in the same period. Both failures trace to the same structural problem: enrollment criteria and diagnostic thresholds were not designed around dengue's actual kinetics. With 390 million annual infections, 500,000 severe cases, and 20,000 deaths, the absence of any specific treatment is not acceptable as a stable equilibrium, but the current trial infrastructure cannot generate the evidence needed to change it.

NS1 antigen rapid diagnostic tests can detect dengue in the first few days of illness before antibody tests become positive, but their sensitivity in the first 48 hours — the window where a viremia-based enrollment criterion would be meaningful — is insufficient for confident trial enrollment. Serology-based enrollment detects past or resolving infection, not current viremic state. PCR is the most sensitive method for confirming early viremia but is not available at point-of-care in most dengue-endemic settings, creating a logistical gap between where trials are conducted and where rapid viremia confirmation is feasible. No alternative primary endpoint — clinical severity, hospitalization, symptom duration — has been validated as a surrogate for antiviral activity with sufficient regulatory acceptance to substitute for viremia in a registration trial. DNDi has trials planned for Brazil in late 2026, but the viremia endpoint problem has not been structurally resolved prior to those trials.

Two parallel workstreams are needed. First, a point-of-care viremia diagnostic with sensitivity sufficient to confirm active viremia at the time of enrollment — enabling reliable patient selection within the treatment window. Second, a validated clinical endpoint or composite endpoint that regulators will accept as evidence of antiviral efficacy when viremia measurement is unreliable at enrollment — which requires regulatory science investment, not additional drug discovery. Neither is a conventional drug development activity, which is why neither is being led by the pharmaceutical companies whose compounds are failing in trials.

A diagnostic design team could specify the sensitivity and turnaround-time requirements for a point-of-care dengue viremia test that would solve the enrollment timing problem, and assess what sensing technologies are closest to meeting those requirements. A clinical trial design team could model alternative primary endpoint options — symptom duration, biomarker panels, severity composites — and evaluate their statistical power and regulatory precedent. A systems team could map the care-seeking delay problem: what structural features of dengue healthcare-seeking in endemic settings produce the average 3–5 day presentation lag, and what community-level interventions could pull presentation earlier into the viremic window?